To explore the intracellular pathways activated by vasopressin receptors, the effects of arginine vasopressin (AVP) and its analogues mediating glycine (Gly)-induced Cl ؊ currents (I Gly ) were examined in acutely dissociated rat hippocampal CA1 neurons using the whole-cell patch recording technique. AVP and its analogues inhibited I Gly in a concentration-dependent manner. The inhibitory actions of AVP(4 -9) (AVP metabolite) and NC-1900 (AVP(4 -9) analogue) were reversed by a V 1 receptor antagonist, or pretreatment with 1,2-bis The hypothalamic vasopressin-containing neurons project to the hippocampal regions (4, 5). Autoradiographic ligand-binding studies found vasopressin receptors in the pyramidal cell layer of the hippocampus (6, 7). The vasopressin receptor in the hippocampus has been shown to be the V 1 subtype in histological studies using a 3 H-labeled V 1 antagonist (8, 9). Moreover, the possible existence of V 2 receptor in the rat hippocampus has also been suggested at the mRNA level (10). Extracellular recording revealed an increase of firing rate of hippocampal neurons stimulated by AVP (11). In addition, AVP has been shown to induce an increase of spike discharge in the hippocampal CA1 pyramidal neurons in studies using microelectrode techniques (12). In both electrophysiological (9, 11) and behavioral (13, 14) studies, the effect of AVP was blocked by a selective V 1 receptor antagonist. It has also been reported that AVP induced the production of IP 3 through the V 1 receptor in rat cultured hippocampal neurons (15, 16). Brinton and McEwen (17) demonstrated that AVP potentiates the norepinephrine-induced cAMP accumulation in a calcium-dependent manner in the rat hippocampal slice preparation through the V 1 receptor. It has been demonstrated that the activation of V 1a receptor potentiated the V 2 receptor-mediated cAMP accumulation in Chinese hamster ovary (CHO) cells transfected with both receptor cDNAs (18). However, the specific mechanism by which cAMP accumulates as a consequence of V 1 receptor activation has yet been elucidated for hippocampal neurons.
1 synthesized in the supraoptic and paraventricular nuclei of the hypothalamus exerts antidiuretic and vasopressor effects. AVP also has a neuroregulatory effect in the central nervous systems including learning and memory (1) . Vasopressin receptors have been classified into two major subtypes, named V 1 and V 2 receptors, based on their intracellular transduction mechanisms. The V 1 receptor is associated with phosphoinositide (PI) turnover (2) , while the V 2 receptor activates adenylate cyclase (3) .
The hypothalamic vasopressin-containing neurons project to the hippocampal regions (4, 5) . Autoradiographic ligand-binding studies found vasopressin receptors in the pyramidal cell layer of the hippocampus (6, 7) . The vasopressin receptor in the hippocampus has been shown to be the V 1 subtype in histological studies using a 3 H-labeled V 1 antagonist (8, 9) . Moreover, the possible existence of V 2 receptor in the rat hippocampus has also been suggested at the mRNA level (10) . Extracellular recording revealed an increase of firing rate of hippocampal neurons stimulated by AVP (11) . In addition, AVP has been shown to induce an increase of spike discharge in the hippocampal CA1 pyramidal neurons in studies using microelectrode techniques (12) . In both electrophysiological (9, 11) and behavioral (13, 14) studies, the effect of AVP was blocked by a selective V 1 receptor antagonist. It has also been reported that AVP induced the production of IP 3 through the V 1 receptor in rat cultured hippocampal neurons (15, 16) . Brinton and McEwen (17) demonstrated that AVP potentiates the norepinephrine-induced cAMP accumulation in a calcium-dependent manner in the rat hippocampal slice preparation through the V 1 receptor. It has been demonstrated that the activation of V 1a receptor potentiated the V 2 receptor-mediated cAMP accumulation in Chinese hamster ovary (CHO) cells transfected with both receptor cDNAs (18) . However, the specific mechanism by which cAMP accumulates as a consequence of V 1 receptor activation has yet been elucidated for hippocampal neurons.
The intracellular cAMP levels may be modified by calcium through regulation of the activity of some adenylate cyclase isoforms. Nine subtypes of adenylate cyclase have been identified by cloning and expression studies, and they have been divided into six subfamilies based on their functional properties and sequence similarities: type 1, type 2-like group (types 2, 4 and 7), type 3, type 5-like group (types 5 and 6), type 8, and type 9 (19 -23) . The presence of types 1, 2, 4, and 8 messenger RNAs was revealed by the polymerase chain reaction in pyramidal neurons in the CA1 region (21, (23) (24) (25) . The types 1 and 8 adenylate cyclases are regulated by not only Ca 2ϩ /calmodulin (CaM) but also by G s (21, 26) . The type 2 adenylate cyclase is insensitive to Ca 2ϩ /CaM but is regulated by G s (27) . The glycine (Gly)-induced response is modulated by either protein kinase A (PKA) or protein kinase C (PKC) (28 -33) . In addition, we and others have shown that freshly dissociated rat hippocampal neurons respond to Gly (34 -36) . Therefore, to explore the intracellular pathways activated by vasopressin receptors, we have examined the affects of AVP and its analogues on the Gly-induced inhibitory responses in acutely dissociated pyramidal neurons from the rat hippocampal CA1 region using the patch-clamp technique.
EXPERIMENTAL PROCEDURES
Preparation-Hippocanpal pyramidal neurons were acutely dissociated from the rat CA1 region, as described elsewhere (37) . Briefly, 2-3-week-old Wistar rats were anesthetized with ether and decapitated. The brain was quickly removed from the skull and was sliced at a thickness of 400 m with a microslicer (DTK-1000; Dosaka, Kyoto, Japan). The slices were then treated with Pronase (1 mg in 6 ml) for 15 min at 31°C and subsequently with thermolysin (1 mg in 6 ml) under the same conditions. The CA1 region of the slice was removed by micropunching and mechanically triturated with fire-polished Pasteur pipettes in a 35-mm plastic culture dish (Primaria 3801; Becton Dickinson, Franklin Lakes, NJ) under a phase-contrast microscope (BH-2; Olympus, Tokyo, Japan). The dissociated CA1 neurons adhered to the bottom of the dish within 20 min.
Electrical Measurements-Electrical measurements were performed with the nystatin perforated patch recording technique (38) . In some experiments, the conventional whole-cell patch recording mode was used (Fig. 6C) . The resistance between the recording electrode filled with the internal pipette solution and the reference electrode was 5-8 megohms. The current and voltage were measured with a patch-clamp amplifier (CEZ-2300; Nihon Kohden, Tokyo, Japan), filtered at 1 kHz (E-3201B; NF Electronic Instruments, Tokyo, Japan) and monitored on both an oscilloscope (VC-11; Nihon Kohden) and a pen recorder (RJG-4124; Nihon Kohden). The data were stored on videotapes after digitalization with a pulse-coded modulation processor (RP-880; NF Electronic Instruments). The membrane potential was held at Ϫ40 mV throughout the experiment, except when examining the current-voltage (I-V) relationships (Fig. 4C) . All experiments were performed at room temperature (22-24°C).
Solutions-The ionic composition of the incubation solution was (mM): 124 NaCl, 
was synthesized by Nippon Chemiphar Co., Ltd. (Saitama, Japan).
Stock solutions of db-cAMP, IBMX, forskolin, and PMA were prepared in dimethyl sulfoxide (Me 2 SO) and diluted to their final concentrations in standard solution just before use. The final concentration of Me 2 SO was always less than 0.1%. It did not induce any ionic current and had no effect on the Gly-induced response at the concentrations used. The other drugs were dissolved in the standard external solution just before use. Drugs were applied by the "Y-tube system," which enables a solution to exchange within 20 ms (39) .
Statistics-The data are presented as the mean Ϯ S.E. The results were analyzed with the Student's t test, paired t test, or Dunnett's multiple comparison test, and a p value of Ͻ 0.05 was considered to be significant.
RESULTS

Effects of Arginine Vasopressin and Its Analogues-Rapid application of 10
Ϫ4 M Gly at 2-min intervals induced constant peak inward currents for 60 min at a holding potential (V h ) of -40 mV under the voltage-clamp conditions. Strychnine, a competitive Gly receptor antagonist, inhibited strongly the Glyinduced current (I Gly ) at a concentration of 10 Ϫ7 M (Fig. 1B, a) . AVP or DDAVP alone did not induce any noticeable current at concentrations up to 10 Ϫ6 M. AVP(4 -9), a AVP metabolite in the brain (40) , or NC-1900, a synthetic analogue of AVP(4 -9), also did not induce currents. However, the I Gly was gradually inhibited during the continuous application of these peptides for 10 min (Fig. 1A, a-d) . The inhibition completely recovered to the control levels after washing out the peptides. ]AVP alone induced no current and had no effect on I Gly . However, the inhibitory actions of 10 Ϫ6 M NC-1900 and 10 Ϫ6 M AVP(4 -9) on I Gly were completely blocked by the pretreatment with the V 1 antagonist (Fig. 2A, a and b) . Effect of a V 2 Receptor Antagonist-To explore the contribution of V 2 receptors, the effect of OPC-31260, a selective V 2 receptor antagonist (42), was examined. Pretreatment with 10 Ϫ6 M OPC-31260 alone induced no current and had no effect on I Gly . The inhibitory action of 10 Ϫ6 M DDAVP on I Gly was completely blocked by pretreatment with OPC-31260 (Fig. 3A,  a) , whereas the action of NC-1900 on I Gly was not affected (the percentage of inhibition of I Gly was still 48.3 Ϯ 5.2%, n ϭ 4) (Fig. 3A, b) . The concentration-inhibition relationships between the peptides and the V 2 antagonist are shown in V 2 antagonist completely blocked this peptide action (Fig. 3C) .
Effect of NC-1900 on I Gly -Since NC-1900 had the most potent inhibitory action on I Gly , the concentration-response relationship was examined. All currents induced by Gly at various concentrations with or without 10 Ϫ6 M NC-1900 were normalized to the peak current induced by 10 Ϫ4 M Gly alone (asterisk in Fig. 4A ). NC-1900 inhibited the maximum value of the concentration-response relationship for Gly without affecting the apparent K D (8.5 ϫ 10 Ϫ5 M and 6.5 ϫ 10 Ϫ5 M for with and without NC-1900, respectively) or the hill coefficient (1.01 and 1.02, respectively), indicating that the inhibition is noncompetitive. NC-1900. These E Gly values were close to the Cl Ϫ equilibrium potential (E Cl ) of -21.0 mV (arrow) calculated from the Nernst equation based on the given external and internal Cl Ϫ concentrations (161 and 70 mM, respectively). The inhibition of I Gly by NC-1900 did not show any voltage dependence. The desensitization rates also did not appear to vary with NC-1900 application (Fig. 4B, a) (2) and results in the elevation of [Ca 2ϩ ] i , the effect of [Ca 2ϩ ] i on the I Gly inhibitory actions of these peptides was examined. The CA1 neurons were loaded with 5 ϫ 10 Ϫ6 M BAPTA-AM, a membrane-permeable Ca 2ϩ chelator, for 2 h. The inhibitory action of 10 Ϫ6 M NC-1900 on I Gly was completely abolished in BAPTA-AM-treated neurons (Fig. 5A, a) . The inhibition by 10 Ϫ6 M AVP(4 -9) on I Gly was also blocked in the BAPTA-AMtreated neurons (Fig. 5A, b) . On the other hand, the inhibitory action of 10 Ϫ6 M AVP was only partially blocked in the BAPTA-AM-treated neurons, while that of 10 Ϫ6 M DDAVP was not affected at all (Fig. 5A, c and d) . Fig . 5B summarizes the effect of BAPTA-AM for these peptide actions on I Gly . The percentages of inhibition of NC-1900, AVP(4 -9), AVP, and DDAVP in the BAPTA-AM-treated neurons were 9.9 Ϯ 1.2% (n ϭ 4), 6.8 Ϯ 3.7% (n ϭ 5), 17.2 Ϯ 1.8% (n ϭ 6), and 27.2 Ϯ 1.7% (n ϭ 4), respectively. The inhibitory effects of NC-1900, AVP(4 -9) and AVP were significantly removed by BAPTA-AM treatment (p Ͻ 0.01 for NC-1900 and AVP(4 -9), and p Ͻ 0.05 for AVP; Student's t test).
Calcium Dependence of NC-1900 Inhibitory Action-Since the NC-1900 action on I Gly through the V 1 receptor was most potent among the examined peptides (Fig. 1) , the following experiments were carried out. First, the Ca 2ϩ dependence for the inhibitory action of NC-1900 on I Gly was investigated. After the I Gly was inhibited by the pretreatment with 10 Ϫ6 M NC-1900 in a standard external solution for 10 min, the external solution was changed to Ca 2ϩ -free external solution containing 2 mM EGTA. The inhibitory action of NC-1900 persisted (Fig.  6A) -ATPase inhibitor which depletes Ca 2ϩ in the IP 3 -sensitive Ca 2ϩ storage sites (IICR), did not affect the peak amplitude of I Gly , but facilitated slightly the desensitization phase of I Gly⅐ The inhibitory action of NC-1900 on I Gly was completely blocked by the pretreatment with thapsigargin (n ϭ 4) (Fig. 6B, a) , suggesting the Ca 2ϩ release from IICR in the presence of NC-1900. Ryanodine depletes the Ca 2ϩ release from caffeine-sensitive intracellular Ca 2ϩ storage sites (CICR). Even after the 10 Ϫ2 M caffeineinduced outward current was considerably reduced by a continuous perfusion with 10 Ϫ6 M ryanodine, the inhibitory effect of NC-1900 on I Gly was still observed, though the inhibition ratio of I Gly by NC-1900 was reduced from 44.3 Ϯ 4.6% of control (n ϭ 5) to 35.0 Ϯ 2.3% (n ϭ 4) in the presence of ryanodine (Fig. 6B, b) .
In the conventional whole-cell patch recording mode, the inhibitory action of I Gly by NC-1900 was also observed (42.4 Ϯ 5.6%, n ϭ 5) (Fig. 6C, open circles) . Therefore, the direct modification of IP 3 was examined by the intracellular perfusion with heparin (5 mg ml These results strongly support the hypothesis that Ca 2ϩ release from the IICR is involved in the inhibitory action of NC-1900 on I Gly .
Effects of Ca 2ϩ /CaM Inhibitors-In order to clarify the signal transduction pathway following the intracellular free Ca 2ϩ on the NC-1900 action, the possible contribution of Ca 2ϩ /CaM and CaM-dependent kinase II was investigated. W-7, trifluoperazine (TFP), and chlorpromazine (CPZ) are known Ca 2ϩ / CaM inhibitors. The inhibitory action of NC-1900 on I Gly was blocked in a concentration-dependent fashion by treatment with 10 Ϫ5 M W-7, TFP, or CPZ, although these compounds alone had no effect on the I Gly (Fig. 7, A, a-c, and B) . In Fig. 7B , the open circle represents the percentage of inhibition of the I Gly by 10 Ϫ6 M NC-1900 in the absence of these inhibitors. W-5 used as a negative control for W-7 had no effect. On the other hand, 10 Ϫ6 M KN-62, a potent CaM-dependent kinase II inhibitor, did not affect the inhibitory action of NC-1900 on I Gly (the inhibition of I Gly was 41.7 Ϯ 7.9%, n ϭ 8) (Fig. 7A, d) . The results indicate that Ca 2ϩ /CaM is involved in the inhibition of I Gly by NC-1900.
Effects of Protein Kinase A and C Modulators-The hydrolysis of PI stimulated by the activation of V 1 receptor produces second messengers such as IP 3 and diacylglycerol (DAG), which activate PKC. The PKC would then phosphorylate the Gly receptor and modulates Gly response (30, 31, 33). The activation of PKA reduces the Gly response in the substantia nigral (29) and the ventromedial hypothalamic neurons (28) . Therefore, the modulatory effect of either PKC or PKA on I Gly was examined to clarify whether these protein kinases were involved in the inhibitory action of NC-1900 on I Gly .
OAG (3 ϫ 10
Ϫ6 M), a membrane permeable DAG analogue, and 10 Ϫ7 M PMA, a PKC activator, significantly potentiated the I Gly to 1.21 Ϯ 0.1 (n ϭ 5) and 1.17 Ϯ 0.05 (n ϭ 4) times that of the control, respectively. Chelerythrine (3 ϫ 10 Ϫ6 M), a PKC inhibitor, hardly affected the I Gly (0.98 Ϯ 0.02, n ϭ 5). Forskolin (10 Ϫ6 M), an activator of adenylate cyclase, inhibited the I Gly by 0.37 Ϯ 0.03 (n ϭ 4). The mixture of 10 Ϫ6 M IBMX, a phosphodiesterase inhibitor, and 10 Ϫ4 M db-cAMP, a membrane-permeable cAMP analogue, also inhibited the I Gly by 0.45 Ϯ 0.09 (n ϭ 5). Rp-cAMPS (10 Ϫ4 M), a potent PKA inhibitor, potentiated the I Gly to 1.42 Ϯ 0.08 (n ϭ 4) (Fig. 8A ). Another PKA inhibitor, H-89 (10 Ϫ6 M) also potentiated the I Gly to 1.42 Ϯ 0.04 (n ϭ 5). These results were the same as those reported previously (28, 29, 32) .
NC-1900 still could inhibit the I Gly to a similar extent in the presence of PKC modulators (Fig. 8B, a-c) . The inhibitory effects of NC-1900 on I Gly in the presence of PKC modulators are summarized in Fig. 8B (d) . The relative values of I Gly inhibition by 10 Ϫ6 M NC-1900 in the presence of OAG, PMA, and chelerythrine were 0.43 Ϯ 0.06 (n ϭ 4), 0.44 Ϯ 0.02 (n ϭ 4), and 0.42 Ϯ 0.05 (n ϭ 5), respectively. The results indicate that the PKC pathway is unlikely to participate in the inhibition of I Gly by NC-1900.
The inhibitory action of NC-1900 on I Gly was, however, completely removed in the presence of PKA activators or inhibitors, suggesting the PKA pathway is involved in the NC-1900 action. The percentage of inhibition of the I Gly by NC-1900 (10 Ϫ6 M) were 3.0 Ϯ 2.7% (n ϭ 5), 7.2 Ϯ 5.5% (n ϭ 4), 2.7 Ϯ 2.1% (n ϭ 4) and 1.8 Ϯ 2.1% (n ϭ 5) in the presence of forskolin, mixture of IBMX and db-cAMP, Rp-cAMPS, and H-89, respectively (Fig. 9,  A and B, a) . The inhibitory effect of DDAVP was also reversed in the presence of Rp-cAMPS or H-89. The relative value of I Gly in the presence of 10 Ϫ4 M Rp-cAMPS was 0.98 Ϯ 0.04 (n ϭ 4) (Fig. 9B, b) , and that in the presence of 10
Ϫ6 M H-89 was 1.01 Ϯ 0.03 (n ϭ 4). Furthermore, the application of 2Ј,5Ј-dideoxyadenosine (DDA), a membrane-permeable adenylate cyclase inhib- M) in the presence of DDA (10 Ϫ3 M) were 7.2 Ϯ 3.4% (n ϭ 5) and 8.3 Ϯ 3.7% (n ϭ 4), respectively (Fig. 9C, a and b) . The results in the presence of DDA at various concentrations are summarized in Fig. 9C (c) . The open symbols represent the percentage of inhibition of the I Gly by NC-1900 and DDAVP in the absence of DDA (45.1 Ϯ 6.7% and 31.1 Ϯ 2.9%, respectively, n ϭ 4 to 5). DDA blocked the inhibitory actions of NC-1900 and DDAVP in a concentration-dependent manner.
Effect of Co-application of AVP (4 -9) and DDAVP-To clarify the interaction between the V 1 and V 2 receptors, we examined the effect of co-application of 10 Ϫ6 M AVP(4 -9) and DDAVP, which act on V 1 and V 2 receptors, respectively. Each peptide inhibits the I Gly to a similar extent at this concentration (Fig.  1A, b and d) . The mixture of AVP(4 -9) and DDAVP inhibited the I Gly by 32.1 Ϯ 2.5% (Fig. 10, n ϭ 4) . Thus, the inhibitory effect of the mixture was similar to that of each peptide alone.
DISCUSSION
V 1 or V 2 Receptor-mediated Inhibitory Actions on I Gly -
The present study has demonstrated that AVP and its analogues inhibit the I Gly in the pyramidal neurons of the hippocampal CA1 region. NC-1900 had the most potent inhibitory action among these peptides. In previous electrophysiological (11, 12) and biochemical (15-17) studies using the hippocampal preparations, AVP exerted its effect at concentrations between 10 Ϫ9 M and 10 Ϫ6 M. In the present study, AVP inhibited the I Gly at the concentration between 10 Ϫ10 M and 10 Ϫ6 M. The administration of AVP, AVP(4 -9) or NC-1900 to mice reduced the onset time of strychnine-or picrotoxin-induced convulsion, though these peptides themselves did not induce any convulsion. 2 Unlike strychnine, these peptides may not inhibit the I Gly completely even at higher concentration.
The inhibitory action of AVP on I Gly was partially blocked by either 10 (Figs. 2  and 3 ), or 10 Ϫ6 M OPC-31260, a V 2 antagonist. The mixture of both antagonists completely blocked the AVP action (Fig. 3) . In addition, the AVP action was partially removed in the BAPTA-AM loaded neurons (Fig. 5) . The results indicate that the AVP action on I Gly is mediated not only by V 1 receptor but also by V 2 receptor. It has been suggested that all the effects of AVP on the neurons in hippocampal slices are mediated through V 1 receptors (9, 11, 16) . However, the possible existence of V 2 receptor in the rat hippocampus has been suggested by the presence of V 2 receptor mRNA (10) . In addition, we demonstrated that DDAVP, a selective V 2 agonist, inhibited the I Gly , and its action was blocked by V 2 antagonist. Thus, present data indicate the existence of both V 1 and V 2 receptors in the hippocampal CA1 neurons.
Mü hlethaler et al. (45) reported that AVP and oxytocin (OT) 2 O. Maeda and K. Hirate, unpublished data. exerted an electrophysiological effect via uterine-type OT receptor on non-pyramidal neurons in the hippocampus. However, Mizuno et al. (12) showed, using intracellular recording techniques, that 10 Ϫ6 M AVP increased the spike discharge of hippocampal pyramidal neurons. Chepkova et al. (46) also demonstrated that 10 Ϫ10 M AVP increased the amplitude and slope of EPSPs of the hippocampal pyramidal neurons, using intracellular recording techniques. Brinton and McEwen (17) demonstrated that AVP enhanced the cAMP accumulation induced by norepinephrine in cultured hippocampal neurons, whereas OT did not. Similarly, it has been reported that 10 Ϫ7 M AVP leads to IP 3 production in rat hippocampal slices via V 1 receptors, whereas OT has no affect (15) . Both AVP and OT at the concentration of 2.5 ϫ 10 Ϫ7 M induced IP 3 production in cultured hippocampal neurons, but these affects were exerted through the V 1 receptor (16) . In addition, in autoradiographic studies, the AVP receptors were observed in the pyramidal cell layer (6, 7) . These results suggest that the inhibitory effect of AVP on the I Gly observed in this study was exerted through the V 1 receptors in the hippocampal pyramidal neurons.
The inhibitory effects of both NC-1900 and AVP(4 -9) on I Gly were not blocked by the V 2 antagonist but by the V 1 antagonist, and these inhibitory actions were completely reversed by the pretreatment with BAPTA-AM. These results indicate that NC-1900 and AVP(4 -9) activate the V 1 receptor in hippocampal neurons. Blockade of the AVP(4 -9) effect by the V 1 antagonist has also been reported in other studies using both neurochemical (16, 47) and behavioral paradigms (48) . However, the autoradiographic studies indicated that binding sites for AVP (4 -9) are distinct from that of putative V 1 receptors in the hippocampus or other brain regions (49, 50 2 The discrepancies among these studies suggest two alternative explanations. First, AVP, AVP(4 -9), and NC-1900 recognized different regions of the V 1 receptor, while V 1 antagonist recognizes all of them. Second, these peptides recognize the different subtypes of V 1 receptor while V 1 antagonist recognizes all of them. The recent molecular cloning of peripheral vasopressin receptors has revealed the presence of 5-9 different bands in the human and rat genomic DNA, which hybridized with a probe for the rat V 1 receptor cDNA (51) . Additional members of the vasopressin receptor gene family may well exist. Further functional investigations are necessary to confirm this hypothesis.
Intracellular Mechanisms of V 1 Receptor-mediated ActionThe inhibitory action of NC-1900 on I Gly was completely abolished (Fig. 6C) in the conventional whole-cell recording using the patch pipette filled with heparin or anti-IP 3 . This result suggests that IP 3 is involved in vasopressin transduction. Both AVP and AVP(4 -9) induced the production of IP 3 in cultured hippocampal neurons through activation of the V 1 receptor (16) . Thus, these results suggest that the inhibitory actions of NC-1900, AVP(4 -9) and AVP on I Gly through the V 1 receptor are mediated by IP 3 . In addition, the NC-1900 action was completely blocked by the treatment with thapsigargin (Fig.  6B, a) , suggesting the involvement of Ca 2ϩ release from IICR in the inhibitory action of NC-1900. However, the inhibitory effect of NC-1900 was also suppressed slightly by treatment with ryanodine (Fig. 6B, b) . Such a minor effect of ryanodine might be due to the close coupling or interaction between IICR and CICR (52) rather than a partial involvement of CICR. Also, the inhibitory action of NC-1900 on I Gly was not affected in Ca 2ϩ -free external solution (Fig. 6A) but was blocked by chelating [Ca 2ϩ ] i with BAPTA-AM (Fig. 5A, a, and B) . These results clearly indicate that the main source of the intracellular free Ca 2ϩ increase in the presence of NC-1900 is IICR. The inhibitors of Ca 2ϩ /CaM block the inhibitory action of NC-1900 on I Gly (Fig. 7) . Interestingly, the action of NC-1900 was not affected by PKC activators or inhibitors but was suppressed by PKA modulators (Figs. 8 and 9 ). Brinton and McEwen (17) demonstrated that AVP facilitated the norepinephrine-induced cAMP accumulation in the hippocampal slices, and this facilitation was blocked by TFP. These results may support the present findings that the Ca 2ϩ /CaM-sensitive adenylate cyclase (type 1 or 8) mediates the inhibitory actions of NC-1900 and AVP(4 -9) on I Gly . Previous biochemical studies have shown that AVP alone does not elevate cAMP level in the hippocampal slice preparation (17, 53, 54) . In this study, however, AVP and its analogues exerted an inhibitory action on I Gly that was mediated by PKA activation. This result strongly suggests that these peptides can induce cAMP accumulation in dissociated hippocampal neurons. Brinton and Brownson (55) have demonstrated that AVP(4 -9) induces cAMP accumulation in cultured hippocampal neurons. Brinton et al. (16) also indicated that AVP(4 -9) elevated IP 3 levels in cultured hippocampal neurons, and its effect was blocked by V 1 antagonist. In the present study, AVP(4 -9) inhibited I Gly through the V 1 receptor (Figs. 1 and 2 ). These results indicate that AVP(4 -9) alone, which stimulates the V 1 receptor, can induce cAMP accumulation through IP 3 production in the hippocampal neurons. In vascular smooth muscle cells, AVP alone induces cAMP accumulation by activating the Ca 2ϩ /CaM-sensitive adenylate cyclase (type 3) expressed in the smooth muscle cells through the V 1 receptors and modulates the isoproterenolstimulated cAMP accumulation (56) . Brinton and McEwen (17) have also reported that the facilitative effect of AVP on norepinephrine-induced cAMP accumulation depends on [Ca 2ϩ ] o . In cultured hippocampal neurons, the activation of V 1 receptors induced Ca 2ϩ influx (16), suggesting the necessity of extracellular Ca 2ϩ for eliciting V 1 receptor-mediated responses. Furthermore, the activation of Nmethyl-D-aspartate (NMDA) receptors in the CA1 region increased the level of cAMP through the activation of a Ca 2ϩ / CaM-sensitive adenylate cyclase (57, 58) . The increase of cAMP induced by NMDA depended on the presence of extracellular Ca 2ϩ (57) . Based on these results, they suggested that Ca 2ϩ influx was required for the activation of Ca 2ϩ /CaM-sensitive adenylate cyclase. In the present study, however, the inhibitory effect of NC-1900 on I Gly was not mediated by Ca 2ϩ influx but by the rise of intracellular free Ca 2ϩ released from IICR, suggesting the possible activation of Ca 2ϩ /CaM-sensitive adenylate cyclase in the absence of Ca 2ϩ influx. Interestingly, it has been reported that ␥-aminobutyric acid-induced current was also modulated by an increase of intracellular free Ca 2ϩ released from intracellular Ca 2ϩ storage sites but not by Ca 2ϩ influx in cultured porcine pituitary intermediate lobe neurons (59) . In addition, Zhang et al. (56) demonstrated that influx of Ca 2ϩ from extracellular medium appears to contribute little to the AVP-induced enhancement action of isoproterenol-stimulated cAMP accumulation in the smooth muscle cells.
A pathway that is consistent with the present data is summarized in Fig. 11 . Both AVP(4 -9) and NC-1900 produce IP 3 through the activation of V 1 receptors. The IP 3 induces Ca 2ϩ release from IICR, and the increased intracellular free Ca 2ϩ is bound to CaM. The Ca 2ϩ /CaM activates the Ca 2ϩ /CaM-sensitive adenylate cyclase. Activation of adenylate cyclase results in the activation of PKA, which inhibits the Gly-induced Cl Ϫ current. However, AVP activates both V 1 and V 2 receptors, and DDAVP inhibits the I Gly through the V 2 receptor by activating G s . In CHO cells transfected with the V 1a and V 2 receptor cDNA, V 2 -induced cAMP accumulation was synergistically potentiated by the stimulation of V 1a receptor transduction pathway. However, this is not the case in the rat hippocampal CA1 neurons because the co-application of V 1 and V 2 receptor selective agonists, AVP(4 -9) and DDAVP, had no additive or synergistic effect in the I Gly inhibition (Fig. 10) . The stimulation of V 1 receptor activates Ca 2ϩ /CaM-sensitive adenylate cyclase (type 1 or 8). On the other hand, the stimulation of V 2 receptor activates Ca 2ϩ -insensitive adenylate cyclase (type 2 or 4). The type 2 adenylate cyclase is also activated by PKC (26) . We demonstrated, however, that PKC was not involved in the actions of AVP and its analogues, suggesting that only type 2 adenylate cyclase is not involved in the intracellular pathways stimulated by these peptides. The existence of type 4 adenylate cyclase in the mouse hippocampus has been demonstrated (25) . To explain the lack of additive effect in the inhibitory action of I Gly by co-application of V 1 and V 2 agonists (Fig. 10) , two alternative possibilities can be raised. 1) Activation of V 1 and V 2 receptors share a common intracellular pathway. The amounts of intracellular mediators such as PKA and glycine receptors might be the limiting factors for the inhibitory actions of these peptides. However, this is not likely because 10 Ϫ6 M NC-1900 inhibited I Gly more than co-application of 10 Ϫ6 M V 1 and V 2 agonists employed in Fig. 10 (Fig. 1B) . 2) the reduction of type 1 adenylate cyclase activity by the activation of V 2 receptor. Type 1 adenylate cyclase is inhibited by the ␤␥-subunit (19) . Further investigation using specific inhibitors is needed to reveal the adenylate cyclase isoforms related to the intracellular pathways stimulated by these receptors.
Recently, it has been demonstrated that AVP induces a [Ca 2ϩ ] i increase in vasopressinergic magnocellular supraoptic nucleus neurons through both phospholipase C (PLC)-and adenylate cyclase-linked signal transduction pathways (60) . They hypothesized three possibilities: first, that AVP activates both V 1 and V 2 receptors; second, that AVP activates a unique vasopressin receptor, which could be coupled to both PLC and adenylate cyclase; and third, that AVP activates V 1 receptor uniquely coupled to PLC whose intracellular cascade could stimulate the cAMP second messenger system. Our results suggest that AVP activate both V 1 and V 2 receptors in the hippocampal pyramidal neurons, consistent with the first hypothesis for magnocellular supraoptic nucleus neurons. In addition, AVP(4 -9) and NC-1900 activation of the V 1 receptor results in the accumulation of cAMP through intracellular pathways, consistent with the third hypothesis. In any case, interestingly, AVP and its analogues require no Ca 2ϩ influx for their inhibitory actions on I Gly in the hippocampal CA1 neurons.
